CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price traded up 2.7% during mid-day trading on Friday . The company traded as high as $2.35 and last traded at $2.26. 2,686 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 33,735 shares. The stock had previously closed at $2.20.
Analyst Ratings Changes
Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price target on shares of CytoMed Therapeutics in a research report on Thursday, October 10th.
View Our Latest Stock Report on CytoMed Therapeutics
CytoMed Therapeutics Trading Up 2.7 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Why Are These Companies Considered Blue Chips?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- The How And Why of Investing in Oil Stocks
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- Canadian Penny Stocks: Can They Make You Rich?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
